Nervous system
Memantine (NMDA receptor antagonist)
An NMDA receptor antagonist that damps excessive glutamate stimulation, which may contribute to neuronal injury; used in moderate to severe Alzheimer disease, alone or with a cholinesterase inhibitor.
Mechanism of action
- In Alzheimer disease, chronic low-level glutamate overstimulation of NMDA receptors lets in too much calcium (excitotoxicity).
- Memantine blocks the open NMDA channel with low affinity and fast kinetics.
- Pathological, tonic activation is reduced while the brief, strong activation needed for learning is spared.
Molecular targets
- NMDA glutamate receptor channel: Uncompetitive (open-channel) blocker
Drugs in Memantine (NMDA receptor antagonist)
- Memantine (By mouth; cleared by the kidney.)
Therapeutic uses
- Moderate to severe Alzheimer disease, alone or added to donepezil
Diseases it treats
Adverse effects
- Dizziness and headache
- Confusion and agitation
- Constipation
Contraindications by condition
- Kidney impairment (Use with care): It is excreted by the kidney and accumulates.
- Epilepsy (Use with care): It may lower the seizure threshold.
Connected topics
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 8, Drugs for Neurodegenerative Diseases, NMDA receptor antagonist
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 60, Special Aspects of Geriatric Pharmacology, Alzheimer disease
Educational reference. Not medical advice, diagnosis or treatment.